The stock of Arbutus Biopharma Corp (ABUS) has seen a -6.67% decrease in the past week, with a -2.53% drop in the past month, and a -6.67% decrease in the past quarter. The volatility ratio for the week is 5.37%, and the volatility levels for the past 30 days are at 5.05% for ABUS. The simple moving average for the past 20 days is -7.16% for ABUS’s stock, with a -13.76% simple moving average for the past 200 days.
Is It Worth Investing in Arbutus Biopharma Corp (NASDAQ: ABUS) Right Now?
The 36-month beta value for ABUS is also noteworthy at 1.22. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for ABUS is 148.63M, and at present, short sellers hold a 7.53% of that float. The average trading volume of ABUS on May 15, 2025 was 1.07M shares.
ABUS) stock’s latest price update
The stock price of Arbutus Biopharma Corp (NASDAQ: ABUS) has dropped by -2.53 compared to previous close of 3.16. Despite this, the company has seen a fall of -6.67% in its stock price over the last five trading days. zacks.com reported 2025-05-14 that Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.10 per share a year ago.
Analysts’ Opinion of ABUS
Many brokerage firms have already submitted their reports for ABUS stocks, with Jefferies repeating the rating for ABUS by listing it as a “Buy.” The predicted price for ABUS in the upcoming period, according to Jefferies is $5 based on the research report published on February 02, 2022 of the previous year 2022.
Jefferies, on the other hand, stated in their research note that they expect to see ABUS reach a price target of $5. The rating they have provided for ABUS stocks is “Hold” according to the report published on February 25th, 2021.
H.C. Wainwright gave a rating of “Buy” to ABUS, setting the target price at $10 in the report published on December 17th of the previous year.
ABUS Trading at -6.27% from the 50-Day Moving Average
After a stumble in the market that brought ABUS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -34.81% of loss for the given period.
Volatility was left at 5.05%, however, over the last 30 days, the volatility rate increased by 5.37%, as shares sank -0.49% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -11.99% lower at present.
During the last 5 trading sessions, ABUS fell by -7.73%, which changed the moving average for the period of 200-days by -19.44% in comparison to the 20-day moving average, which settled at $3.32. In addition, Arbutus Biopharma Corp saw -5.81% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ABUS starting from McElhaugh Michael J., who proposed sale 246,886 shares at the price of $3.26 back on Apr 21 ’25. After this action, McElhaugh Michael J. now owns shares of Arbutus Biopharma Corp, valued at $804,850 using the latest closing price.
McElhaugh Michael J., the Director of Arbutus Biopharma Corp, proposed sale 53,114 shares at $3.20 during a trade that took place back on Apr 15 ’25, which means that McElhaugh Michael J. is holding shares at $170,098 based on the most recent closing price.
Stock Fundamentals for ABUS
Current profitability levels for the company are sitting at:
- -12.3 for the present operating margin
- 0.83 for the gross margin
The net margin for Arbutus Biopharma Corp stands at -11.33. The total capital return value is set at -0.65. Equity return is now at value -79.02, with -57.29 for asset returns.
Based on Arbutus Biopharma Corp (ABUS), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -50.12. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -554.22.
Currently, EBITDA for the company is -68.4 million with net debt to EBITDA at 0.51. When we switch over and look at the enterprise to sales, we see a ratio of 89.43. The receivables turnover for the company is 2.56for trailing twelve months and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.01.
Conclusion
In summary, Arbutus Biopharma Corp (ABUS) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
